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Abstract
Background: Faecal calprotectin correlates with histological and clinical activity in inflammatory bowel disease.
Gastrointestinal bleeding might also increase faecal calprotectin levels, erroneously implying intestinal inflammation;
however, this possibility has not been systematically assessed.
Methods: Sixteen healthy volunteers without gastrointestinal disease and normal faecal calprotectin baseline values
ingested their own blood twice, either by drinking or via nasogastric tube. Quantities of 100ml and 300ml blood were
ingested in a randomised order, with a 28-day wash-out period. Faecal calprotectin, faecal occult blood test, and the
occurrence of melaena were assessed. Faecal calprotectin 50 mg/g was considered elevated.
Results: Melaena was reported by all healthy volunteers after 300ml and by 11/15 healthy volunteers (71%) after 100ml
blood ingestion. One day after ingestion of 300ml blood, 8/16 faecal calprotectin tests were positive compared to 1/16 at
baseline (p¼ 0.016). Faecal calprotectin levels above> 200 mg/g were rarely observed. There was a trend for faecal
calprotectin test positivity also after ingestion of 100ml.
Conclusion: Ingestion of blood resulted in an increase in faecal calprotectin-positive tests. Gastrointestinal bleeding should
be considered as a potential cause of mild faecal calprotectin elevation> 50 mg/g; however, increased faecal calprotectin
above> 250–300 mg/g, the established cut-off for relevant intestinal inflammation in patients with inflammatory bowel
disease, is rare.
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Key summary
Current knowledge
. Faecal calprotectin (fC) correlates with histological and clinical activity in inﬂammatory bowel disease
(IBD); however, the speciﬁcity of this test is low. In addition to inﬂammation, gastrointestinal (GI)
bleeding may be a cause of elevated fC; however, this possibility has not been systematically assessed.
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What is new
. Ingestion of blood can lead to an increase in fC.
. Blood in the GI tract should be considered as a potential reason for mild fC elevation (>50 mg/g); how-
ever, calprotectin levels> 250–300mg/g are unlikely to be caused by upper GI bleeding.
Introduction
Monitoring disease activity in inﬂammatory bowel
disease (IBD) patients remains a challenge in clinical
practice. The current approach includes symptom
assessment, measurement of biomarkers for inﬂamma-
tion, radiology and endoscopy with histology.
However, all of these strategies are associated with sig-
niﬁcant limitations. Symptoms as a means of assessing
disease activity are limited by their subjective nature as
well as a patient’s inability to discriminate between
inﬂammation and functional (post-inﬂammatory) con-
ditions.1–3 Systemic serum markers in the blood are not
speciﬁc to IBD and are frequently normal if inﬂamma-
tion remains restricted to the superﬁcial mucosa.
Endoscopy is the gold standard to assess disease activ-
ity;4,5 however, it is invasive, costly, uncomfortable for
the patient and cannot readily access the entire
intestine.
Calprotectin has emerged as a non-invasive marker
for intestinal inﬂammation.6 It is a calcium-binding
protein abundant in neutrophils;6 its concentration in
the faeces correlates with neutrophilic inﬁltration of the
intestinal mucosa.7 Faecal calprotectin (fC) has been
shown to correlate well also with endoscopic and histo-
logic disease activity in IBD.8–12 Furthermore, it
remains stable in stool samples for several days under
a wide range of temperatures.13
For these reasons, fC is increasingly used in clinical
practice and constitutes an important component of
therapeutic decision making. However, fC as a
marker for IBD activity has several limitations. Due
to the role of neutrophils in many forms of inﬂamma-
tion and the presence of neutrophils in normal blood,
clinical studies have shown elevated fC in a range of
conditions including gastrointestinal (GI)-tract infec-
tions,14 colorectal neoplasia,15–17 microscopic colitis,18
use of non-steroidal anti-inﬂammatory drugs19 and
even upper GI pathologies such as reﬂux esophagitis20
and oesophago-gastric neoplasia.21
GI bleeding may be an important confounder in
assessing IBD activity by fC measurement. The upper
GI tract is a frequent source of intestinal bleeding.
Moreover, the prevalence of GI blood loss in IBD is
high. An increase in fC due to GI-bleeding could erro-
neously indicate active inﬂammation in IBD patients. If
this increase exceeded the established cut-oﬀ for rele-
vant intestinal inﬂammation in patients with IBD, then
this would diminish the validity of this investigation.
To our knowledge, the impact of upper-GI bleeding
on fC levels has not been systematically assessed.
This study reports the results of a randomised inter-
ventional study to assess the eﬀects of deﬁned amounts
of blood delivered to the stomach on fC values.
Established markers of GI bleeding (Faecal Occult
Blood Test (FOBT)) were also obtained. The results sug-
gest that even 100ml of blood can lead to a measureable
increase in fC levels (>50mg/g); however, fC levels
>250–300mg/g typical for acute IBD ﬂares are unlikely
to be caused by upper GI bleeding; however, high values
typical for acute IBD ﬂares were rarely observed.
Materials and methods
Participants and methods
The study was performed at the Division of
Gastroenterology at Triemli Hospital, a tertiary care
centre and teaching hospital in Zurich, Switzerland.
Participants were recruited by advertisement within
the study centre and prospectively enrolled into the
study. Epidemiological characteristics, stool frequency
and consistency (Bristol Stool Scale (BSS)), medical his-
tory, current medication intake were assessed during an
initial screening visit. Exclusion criteria were age below
18 years, acute medical conditions, medical history of
GI disease or former/ current malignancy, GI symp-
toms such as constipation, diarrhoea, abdominal pain
and abdominal surgeries except for appendectomy and
hernia repair older than six months. Blood haemoglo-
bin and fC were measured once during the screening
visit; individuals with anaemia (deﬁned as <13.0 g/dl
for men and 12.0 g/dl for women according to the
World Health Organisation (WHO)) were excluded.
Acute illness (such as an upper airway infection or
gastroenteritis) during intervention were additional
exclusion criteria. Participants had to refrain from
intake of non-steroidal anti-inﬂammatory drugs
(NSAIDs). To limit the number of false positive
FOBT results, participants were asked to refrain from
consuming red meat or vitamin C> 200mg during the
study, according to the recommendation of some
manufacturers of FOBTs.
The study was carried out according to the principles
of the Declaration of Helsinki and the local ethical
committee approved the study protocol (Kantonale
Ethikkommission Zu¨rich, KEK-ZH Nr 2014-0630,
approval on 12 June 2015). All participants provided
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written informed consent before participating in any
study related procedures.
Study procedures
Participants were randomly assigned to ingest
either 100ml or 300ml blood ﬁrst, followed by inges-
tion of the other amount of blood after a washout
period of 28 days. Blood was collected by venous punc-
ture and ingested by participants via drinking or naso-
gastric tube. Stool samples were collected on two
consecutive days at baseline (day–2 and –1), daily on
day 0–7 and day 14 at the study centre or at partici-
pant’s home and sent directly to the laboratory via
mail. Symptoms including melaena, stool frequency
and consistency (Brisol stool scale, BSS) as well as
other symptoms were separately recorded by patient
questionnaires for each study day. A BSS score of 1
and 2 was considered constipation, a BSS score of 5
or 6 was considered diarrhoea.
Calprotectin measurements
Calprotectin is stable up to three days at room tempera-
ture.13 In our study all faecal samples were analysed at
the local diagnostic laboratory within 72 h after collec-
tion. Laboratory technicians were blinded regarding
sample assignment. fC values were determined by
using a commercially available assay, fCALTM
turbo (Bu¨hlmann Laboratories Ltd, Scho¨nenbuch,
Switzerland) on an automatic Analyzer Cobas c501
(Roche Diagnostics Ltd, Rotkreuz, Switzerland). The
quantiﬁcation of calprotectin is based on the technique
of particle-enhanced turbidimetric immunoassay
(PETIA). A positive value was deﬁned as equal as or
greater than 50 mg/g as stated by the manufacturer.
Data analysis
Calculations were performed using GraphPad Prism
version 6.0 or Matlab (version R2015b). Non-para-
metric tests (Wilcoxon matched-pairs signed rank test,
Mann-Whitney U test) or Fisher’s exact test were used
as appropriate. A p value of <0.05 was considered sig-
niﬁcant. Figures were generated using Matlab, Prism
and Adobe Illustrator CC 2015.1.0.
Results
Seventeen healthy volunteers (HVs; mean age 25 years,
range 23–33 years) were enrolled into the study. One
participant developed ﬂu-like symptoms with fever,
myalgia and pharyngitis at baseline and was excluded
(see below). Two additional participants developed
acute gastroenteritis with vomiting on day 7 lasting
three days, and another had symptoms of bacterial pha-
ryngitis with sore throat and fever on day 14. FOBT
and fC measurements on these study days were cen-
sored. One participant dropped out of this study after
ingestion of 300ml blood, leaving 16 individuals for
analysis following 300ml blood ingestion and 15 indi-
viduals for analysis following 100ml blood ingestion,
respectively. Characteristics of the 16 participants are
provided in Table 1. A total of 336 stool samples were
analysed.
All participants tolerated blood ingestion well, with
only minor side eﬀects such as nausea, bloating or
heartburn in 8/16 participants (50%), lasting< 24 h.
Constipation occurred in 6/15 (40%) and 5/16 (31%)
of HVs after ingestion of 100 and 300ml blood, respect-
ively. Diarrhoea was noted by 4/15 (27%) and 4/16
(25%) of HVs after ingestion of 100 and 300ml
blood, respectively.
Melaena
Melaena was reported by all 16 HVs (100%) after
300ml and by 11 out of 15 HV after 100ml blood inges-
tion (71%, Figures 1 and 2). Melaena occurred mainly
on the intervention day and during the following four
days with a peak at days 1 and 2 (p< 0.001 for days
1–3, p< 0.01 for days 0 and 4).
FC measurements
After ingestion of 300ml blood fC levels rose at day 1
(Figure 3) compared to baseline (median 51 mg/g
vs< 20 mg/g on day 1 and 2 before blood ingestion,
p¼ 0.012). Note that, for unexplained reasons, the fC
level of one participant were very high at day –2
(429 mg/g). Due to this outlier, the diﬀerence of day
–2 and 1 was not signiﬁcant (p¼ 0.13).
From day 1–3 after 300ml blood ingestion, 13 out of
46 (26%) stool samples had a fC value of> 50 mg/g
Table 1. Characteristics of participants. The mean standard
deviation is provided.
Description
Numbers (n¼ 16)
Mean standard deviation, range
Gender Male: 4 (25%)
Female: 12 (75%)
Age 25 2.8 years, range 23–33 years
Baseline stool frequency 1.2/day 0.4, range 0.7–2 per day
Baseline stool consistency
(Bristol Stool Scale)
4 0.7, range 2–5
Baseline calprotectin 24 10mg/kg
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compared to two out of 32 (3%) at baseline (p¼ 0.019).
The highest fraction of positive fC was observed at day
1 (seven out of 16 samples, 44%, compared to one out
of 16 at baseline, p¼ 0.016). However positive values
were noted up to day 7 and at least one fC value above
50 mg/g was observed in 10/16 (63%) of HVs (Figures 1
and 2).
A trend for increased fC levels after ingestion of
100ml was present: six out of 44 samples (14%) were
positive from day 1–3 vs one out of 27 (3%) at baseline
(not signiﬁcant). Overall, fC levels above 50 mg/g were
observed in 7/15 (46%) of HVs after ingestion of 100ml
at some point. Pronounced increases in fC levels above
200 mg/g were rarely observed following blood ingestion
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Figure 2. Effects of 100 ml blood on symptoms (melaena), faecal occult blood test (FOBT) and faecal calprotectin (fC) measurements. Top
row: individual results for melaena (left column), FOBT (middle column) and calprotectin (right column) after ingestion of 100ml blood on
each study day. A black box indicates a positive, a white box indicates a negative test result; a cross (X) indicates that there was no stool
sample on that day. Bottom row: cumulative test results for each study day for melaena (left column), FOBT (middle column) and
calprotectin (right column) after ingestion of 100ml blood.
*p< 0.05, **p< 0.01, ***p< 0.001, Fisher’s exact test.
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Figure 1. Effects of 300 ml blood on symptoms (melaena), faecal occult blood test (FOBT) and faecal calprotectin (fC) measurements. Top
row: individual results for melaena (left column), FOBT (middle column) and calprotectin (right column) after ingestion of 300ml blood on
each study day. A black box indicates a positive, a white box indicates a negative test result; a cross (X) indicates that there was no stool
sample on that day. Bottom row: cumulative test results for each study day for melaena (left column), FOBT (middle column) and
calprotectin (right column) after ingestion of 300ml blood.
*p< 0.05, **p< 0.01, ***p< 0.001, Fisher’s exact test.
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(none after 300ml, one individual (6%) after 100ml
ingestion).
Faecal occult blood testing
The FOBT was positive in 14 of 16 HVs (88%) follow-
ing 300ml blood ingestion within days 1–3 compared to
one individual at baseline. Following 100ml blood
ingestion, six of 15 HVs (40%) had a positive test
within days 1–3 compared to no individual at baseline
(Figures 1 and 2).
FOBT and fC levels showed a positive association.
In the test with ingestion of 300ml blood, fC levels were
signiﬁcantly higher in the 43 FOBT-positive samples
than in 118 FOBT-negative samples (p< 0.0001,
Figure 4(a)). Similarly, fC levels were higher in 11
FOBT-positive samples after 100ml blood ingestion
compared to 138 FOBT negative samples (p¼ 0.018,
Figure 4(b)). fC levels were also signiﬁcantly higher in
faecal samples of individuals with 300ml blood inges-
tion in patients that reported melaena (p¼ 0.0005, data
not shown), but no such relationship was present after
100ml of blood ingestion (data not shown).
Two individuals developed viral gastroenteritis and
bacterial ear and nose infection, respectively. Both indi-
viduals were excluded from the study after the onset of
infection. Interestingly, we observed a pronounced,
non-speciﬁc increase in fC levels (>400 mg/g), accom-
panying inﬂammation (Figure 5(a) and (b)).
Discussion
In this prospective interventional study in HVs we ana-
lysed the eﬀect of intraluminal blood in the upper GI
tract on fC levels. We report four key observations:
First, ingestion of 300ml blood results in a signiﬁcant
increase in the likelihood of obtaining a fC-positive test.
Second, elevations of fC values above 200mg/g suggest-
ive of signiﬁcant GI inﬂammation were rare following
blood ingestion. Third, there was a positive association
between fC and FOBT, such that the likelihood of a
FOBT positive stool sample was signiﬁcantly higher in
samples with elevated fC concentration. Finally, rele-
vant fC elevation (>200 ug/g) was observed in two indi-
viduals with acute gastroenteritis and pharyngitis.
Management of IBD patients increasingly relies on
fC measurements as low-cost, non-invasive tests with
high sensitivity for detecting mucosal inﬂamma-
tion.22–26 However, fC cannot distinguish IBD activity
from other inﬂammatory conditions including infec-
tion, ischaemia, neoplasia or toxicity. Our study now
suggests an additional limitation of fC: upper GI bleed-
ing of 300ml blood or more also increases the chances
of a positive fC tests. Chances of a positive test were
highest at day 1 and decreased over time.
The increase in fC values upon blood ingestion was
dose-dependent. The likelihood of a positive fC test was
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signiﬁcantly higher after the 300ml than the 100ml
blood meal. Indeed, there was no signiﬁcant increase
over baseline after ingestion of 100ml blood. Thus,
fC has lower sensitivity for detection of intraluminal
blood than the FOBT. However, when samples with
positive FOBT were compared to samples with negative
FOBT, signiﬁcant diﬀerences in fC levels were observed
upon 100ml as well as 300ml blood ingestion. This
conﬁrms the hypothesis that the presence of blood in
the stool is the cause of increased fC and suggests that
the threshold at which upper GI blood loss can con-
found fC levels is between 100–300ml bleeding.
Remarkably, patient observations (melaena) were
more sensitive for the detection of intraluminal blood
by FOBT and fC indicating that 100ml or 300ml can
leave the GI tract quickly. Only a single stool sample
Blood per day was analysed in this study and the rele-
vant sample was possibly missed in a fraction of
participants.
While intestinal blood can confound fC measure-
ments, fC does not appear to be a sensitive test for
GI bleeding. Assuming each neutrophilic cell carries
approximately 5 pg of fC,27,28 300ml of blood with a
neutrophil count of 5 gigaparticles/l concentrated in
200 g stool would yield an fC concentration of
37.5mg/g and might thus push measurements above
the threshold of 50 mg/g in some patients. Therefore,
migration of neutrophils into the intestinal lumen in
inﬂammation remains the main factor responsible for
pronounced increases in fC levels in IBD, with minimal
contribution of occult or frank intestinal bleeding. The
eﬀect is dose-dependent and, therefore, severe bleeding
from a duodenal ulcer (or an inﬂamed colon in ulcera-
tive colitis (UC)) would be expected to yield higher fC
concentrations than observed in our study.
The level of fC in the stool is prognostically relevant.
Levels< 100mg/g are typically found in clinical remis-
sions while an increase> 150–200mg/g is a poor
prognostic sign with an increased risk of a ﬂare in the fol-
lowing months, especially if present repetitively.29–32 It is
noted that, while intestinal bleeding could cause false-
positive fC measurements in patients, high
levels> 200mg/g were only very rarely observed (i.e. in
one sample of one HV) after ingestion of 300ml blood.
Notwithstanding the above, a false-positive FC test
due to upper GI bleeding could impact on therapeutic
decisions, even if standardised assessment tools are
used (e.g. Utrecht index).33 Even a minor, incremental
FC elevation unrelated to GI inﬂammation could ‘tip
the scales’ and prompt initiation of a new medication.
This underscores the recommendation that in IBD a
therapeutic decision should never be based on a single
parameter.
Two of our participants developed a viral infection
during the course of our study. Interestingly, in
both participants, fC levels increased to >400 mg/g
(Figure 5). Even though these data need to be repro-
duced, it appears that infections of the oropharynx as
well as the GI tract could confound fC measurement.
Additional studies are required to assess the impact of
infections fC measurements.
There are limited data regarding eﬀects of nutrition
on calprotectin levels. One small randomised study
comparing a diet of ﬁsh with a diet of red meat did
not ﬁnd signiﬁcant diﬀerences.34 Other studies found
an inverse correlation of ﬁbre intake and calprotectin
levels.35 A recent review concluded that there are insuf-
ﬁcient data regarding eﬀects of nutrition on fC levels.25
Similarly, data regarding eﬀects of nutrition on FOBT
are limited with most studies not showing any inﬂuence
of diet on FOBT.36,37 Nonetheless, some manufacturers
of FOBT recommend refraining from vitamin
C> 200mg per day and red meat before testing,
which was also done in our study.
Several methods exist for the quantiﬁcation of fC.
The gold-standard is mass spectrometry (MS)
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(e.g. liquid chromatography-mass spectrometry (LC-
MS)); however, this is applied only in the research set-
ting.38 In clinical practice, the fC enzyme-linked
immunosorbent assay (ELISA) remains the
most often applied method for the quantiﬁcation of
fC. The PETIA which was used in our study, was
shown to be equal compared to ELISA in several
studies.39–41
Our study has several limitations: Our study popu-
lation was limited to 16 healthy and young participants.
All individuals were free of signiﬁcant GI symptoms at
inclusion and in the past but endoscopy was not per-
formed to conﬁrm the absence of GI pathology.
Furthermore, although laboratory technicians were
blinded to the study day, participants were not blinded
when reporting symptoms. Moreover, our study simu-
lated a ‘single bleeding event’, whereas GI bleeding usu-
ally occurs continuously or discontinuously for a longer
period of time.
In summary, our study demonstrates that ingestion
of 300ml blood leads to signiﬁcant increase of fC
within the ﬁrst three days; however, high fC values
above 200 mg/g typically observed in severe intestinal
inﬂammation are rarely observed.
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